Our success as a next-generation BioPharma company will be measured by the difference we can
make in the lives of patients fighting serious disease. Members of the press may learn more about
our company, our philanthropy and our focus on innovative medicines by viewing the resources on
this page.

Bristol-Myers Squibb’s Opdivo (nivolumab) is the recipient of Prix Galien Belgium 2015 Award for Best Medicine for the treatment of advanced melanoma and squamous non-small cell lung cancer.

The Prix Galien Belgium Award honors outstanding achievements in improving the human condition and underscores our efforts with the Opdivo early- and late-stage clinical program in patients with some of the hardest-to-treat cancers.